Johnson & Johnson (JNJ)
3 Dividend Stocks That Demand Investor Attention
Dividend stocks pay dividends to their shareholders, representing a portion of the company's profits. Not all companies offer dividends.
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.
Is Johnson & Johnson a Buy Now?
Johnson & Johnson reported results from the second quarter of 2024 on Wednesday, July 17. U.S. pharmaceutical sales grew by nearly 9% year over year in the second quarter.
2 Magnificent S&P 500 Dividend Stocks Down 19% and 41% to Buy and Hold Forever
Starbucks is experiencing weak sales this year, but it has plenty of opportunities to keep growing over the long term. Johnson & Johnson's focus on allocating capital to high-return opportunities has driven a 60-plus year track record of dividend growth.
Why Johnson & Johnson Stock Was a Winner on Wednesday
The healthcare sector mainstay unveiled its latest set of quarterly results. Its second-quarter headline figures comfortably beat the consensus-analyst estimates.
J&J MedTech Navigates Headwinds, Eyes Growth Surge in Second Half of 2024
Johnson & Johnson's (J&J) MedTech arm displayed resilience in its second quarter, navigating inflationary headwinds while prioritizing innovation. The unit, a key driver for J&J, remains committed to full-year growth targets despite temporary setbacks in its vision care business.
Stock Of The Day: Johnson & Johnson Hits Crucial Roadblock — Can It Break Through?
Investors loved the Johnson & Johnson JNJ earnings report. The stock is trading much higher, but it has stalled out around an important resistance level.
Johnson & Johnson Q2: Robust New Product Pipeline
Johnson & Johnson beats market estimates for revenue and EPS in Q2 FY24. A strong product pipeline includes new drugs for ulcerative colitis and lung cancer. JNJ's acquisition of Shockwave Medical positions the company as a leader in the cardiovascular market, potential revenue synergies from integration.
5 Deep Value Stocks To Buy in July
Warren Buffett champions value investing, focusing on undervalued companies with strong fundamentals for long-term growth and stability.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer Joaquin Duato - Chairman and Chief Executive Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Rick Wise - Stifel Terence Flynn - Morgan Stanley Josh Jennings - TD Cowen Dave Risinger - Leerink Partners Danielle Antalffy - UBS Chris Shibutani - Goldman Sachs Joanne Wuensch - Citibank Operator Good morning, and welcome to Johnson & Johnson's Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson climbs after earnings and revenue beat
Johnson & Johnson (NYSE:JNJ) shares climbed 3% after second-quarter earnings fell less than expected. Helped by 8% sales from its pharmaceutical arm, group revenue rose 4.3% to $22.45 billion, which was above the $22.3 billion Wall Street average forecast.
